Kidney cancer drug combo trial halted early – what we know
NCT ID NCT03260504
First seen Dec 16, 2025 · Last updated May 20, 2026 · Updated 15 times
Summary
This early-stage trial tested a combination of two immunotherapy drugs, aldesleukin (IL-2) and pembrolizumab, in 6 people with advanced kidney cancer that had spread. The goal was to find the safest dose and see if the combination could shrink tumors. The study was terminated early, so results are limited, but it aimed to boost the immune system to fight the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.